MDGL Q4 2025 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$321M+210.8% YoY

Gross Profit

$297M92.4% margin

Operating Income

-$60M-18.6% margin

Net Income

-$59M-18.2% margin

EPS (Diluted)

$-2.57

QoQ Revenue Growth

+11.8%

Cash Flow

Operating Cash Flow

-$133M

Free Cash Flow

-$133M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$657M

Stockholders' Equity

$603M

Cash & Equivalents

$199M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$321M	$103M	+210.8%
Gross Profit	$297M	$100M	+197.0%
Operating Income	-$60M	-$67M	+11.0%
Net Income	-$59M	-$59M	+1.4%

Revenue Segments

Reportable Segment

$458M100%